The market players in the ImmunotherapyDrugs Market are actively seeking collaborations and partnerships for thedevelopment of novel immunotherapy drugs. For instance, in April 2018,Bristol-Myers Squibb Company (BMS) and Illumina Inc. collaborated to utilizeIllumina’s next-generation sequencing (NGS) technology to develop and globallycommercialize in-vitro diagnostic (IVD) assays in support of BMS oncologyportfolio. The collaboration helped to develop a diagnostic version of Illumina’sTruSight Oncology 500 assay, including tumor mutation burden (TMB), andmicrosatellite instability for immunotherapies.
Immunotherapy is the managementof a disease by enhancing, suppressing, or inducing an immune response. Someimmunotherapies are designed to magnify or elicit an immune response. They areknown as activation immunotherapies. However, some immunotherapies thatsuppress or reduce the immune response are known as suppressionimmunotherapies. Cell-based immunotherapies are useful for some types ofcancers. Immune effector cells including macrophages, dendritic cells,lymphocytes, cytotoxic T lymphocytes (CTL), natural killer cells (NK Cell),etc., work collectively to protect the body against cancer by aiming atabnormal antigens articulated on the facade of the tumor cells. Therapiesincluding granulocyte colony-stimulating factor (G-CSF), imiquimod, interferonsas well as parts of cellular membrane from bacteria are approved for medicaluse. Some of the others such as IL-7, IL-2, IL-12, synthetic cytosinephosphate-guanosine (CpG) oligodeoxynucleotides and glucans anda variety ofchemokines are involved in preclinical and clinical studies.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/525
An increase in the prevalence ofcancer and a number of autoimmune diseases, the demand for immunotherapy drugsis likely to increase. The impact of these diseases can be ascertained from thefact that cancer caused 9.6 million deaths in 2018, as reported by the WorldHealth Organization (WHO). The organization further stated that around 70% ofdeaths from cancer occur in low and middle-income countries. Moreover, with therising need for mAbs, the immunotherapy drugs market is anticipated to have apositive outlook till the end of the forecast period 2019-2027. MAbs have ahigh affinity towards the specific disease cells as well as areas that requiretreatment. Accordingly, they can be utilized for therapies such asantibody-directed enzyme prodrug therapy and radio immunotherapy. The increaseduse of these antibodies in the drug development process is likely to boost themarket’s revenue making capacity over the forecast period.
Another important factor drivingthe growth prospects of the global immunotherapy drugs market is thematerialization of biosimilars. Dissimilar to generic drugs that have activepharmaceutical ingredients like original drugs, biosimilars are nearlyidentical to their creator biologic compounds. In view of the fact thatbiosimilars are less expensive than biologics therefore the sale of biosimilarsamong the patients and hospitals is likely to rise considerably during theforecast period. This is expected to augment the overall growth of theimmunotherapy drugs market.
On the basis of therapy area, thecancer segment is likely to hold the maximum market share in 2018. The largeshare along with the high growth of this segment is due to the highpredilection for immunotherapy as a first line of treatment in the managementof cancer thereby leading to rising demand for the global immunotherapy drugs.On the basis of product type, the mAbs segment accounted for the maximum shareof the market. The improvement of new drugs as well as the entry of newmolecules such as zanolimumab, elotuzumab, onartuzumab, and obinutuzumab intothe market will drive the growth of the global immunotherapy drugs market overthe forecast period.
Increasing prevalence of cancerand rise in demand from the Asia Pacific region will drive the overallimmunotherapy drugs market
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/immunotherapy-drugs-market-525
According to National CancerInstitute, around 1,685,210 new cases of cancer are likely to be diagnosed inthe U.S. in 2016 and about 595,690 people are estimated to die from thedisease. Since immunotherapy is used as a first line of treatment in themanagement of cancer, the market immunotherapy drugs market will grow accordingly.North America is the largest region in the global immunotherapy drugs marketand is expected to retain its dominance over the forecast period. Asia Pacificis likely to be the fastest-growing market over the forecast period. Theelevated growth of this region can mainly be attributed to low cost ofmanufacturing of these drugs in the region, rising pricing and reimbursementscenario for immunotherapy drugs on the universal level and for major countriessuch as the Belgium, the U.K., France, Italy, Spain, Japan, China, andAustralia. For instance, reimbursement scenario in the U.K. has impacted thecost of the drugs. Keytruda is an immunotherapy drug used for the treatment ofmelanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell cancer(HNSCC), urothelial carcinoma, gastric cancer, and cervical cancer. Keytrudagenerally costs up to US$ 84,000 to the patients. To reduce the cost of thisdrug, the National Health Service (NHS) England, a publicly funded nationalhealthcare system, and Merck & Co. Inc. entered into an agreement in June2018, to reimburse the cost of this drug and provide it for routine use as perthe National Institute for Health and Care Excellence (NICE) recommendations.NICE recommends NHS to provide reimbursements for this drug and make itaffordable for the patients.
Similarly, in April 2018, PfizerInc. and Allogene Therapeutics Inc. entered into an asset contributionagreement to use Pfizer’s portfolio related to allogeneic CAR-T therapy, aninvestigational immune cell therapy, for cancer. This agreement acted as anattractive opportunity for Pfizer Inc. to continue the development of CAR-Ttherapy.
Some of the companies operatingin the immunotherapy drugs market in the current scenario are GlaxoSmithKline,F. Hoffmann-La Roche AG, AbbVie, In., Merck & Co., Inc. Amgen, Inc.,Bristol-Myers Squibb, Eli Lilly and Company, Novartis International AG, AstraZenecaplc and Johnson & Johnson.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/525
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S. Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
